Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis

Mutations in tumor‐suppressor gene BARD1 have been found in inherited and spontaneous breast, ovarian and uterine cancers. BARD1 plays a critical role in DNA repair and ubiquitination as binding partner of BRCA1, with which it colocalizes to nuclear dots. Independently of BRCA1, BARD1 can induce p53‐dependent apoptosis in response to genotoxic stress. Therefore, BARD1 or p53 might be defective in cancer cells spared from apoptosis. We investigated BARD1 and p53 expression in ovarian, breast and non‐small‐cell lung cancers. BARD1 expression was highly upregulated and cytoplasmic in most cancer cells, while weak nuclear staining was observed in the surrounding normal tissue. Maximal BARD1 expression was associated with the most malignant ovarian cancer, clear cell carcinoma. In breast cancer, BARD1 expression was correlated with poor differentiation and large tumor size, established factors of poor prognosis, as well as short disease‐free survival. In contrast to breast and ovarian cancers, no correlation of BARD1 expression with either grade or stage could be determined for lung cancer. RT‐PCR, performed on 10 ovarian cancers, revealed absence of the 5′ portion of the BARD1 transcript in 7 tumors, and sequencing of the remaining 3 identified a missense mutation (A1291G) resulting in an amino acid change of glutamine 406 to arginine. These data suggest that genetic and epigenetic changes might lead to elevated cytoplasmic expression of BARD1 and that cytoplasmic BARD1 might be a poor prognostic factor for breast and ovarian cancers. © 2005 Wiley‐Liss, Inc.

[1]  J. Minna,et al.  Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. , 1992, Oncogene.

[2]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[3]  A. Bowcock,et al.  Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Mansukhani,et al.  Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression , 2003, Oncogene.

[5]  I. Nishimoto,et al.  p53 expression is a factor for prognostic assessment in breast sarcoma , 2002, Breast Cancer Research and Treatment.

[6]  N. Hacker,et al.  Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer , 2004, Clinical Cancer Research.

[7]  E. Miyagi,et al.  Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. , 1995, Gynecologic oncology.

[8]  Stefan Schüchner,et al.  Nuclear–cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1 , 2004, Oncogene.

[9]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[10]  B. Trask,et al.  Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. , 1998, Human molecular genetics.

[11]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[12]  M. Monden,et al.  Mutational analysis of BARD1 in familial breast cancer patients in Japan. , 2003, Cancer letters.

[13]  I. Irminger-Finger,et al.  Mutational spectrum of p53 mutations in primary breast and ovarian tumors. , 2004, Critical reviews in oncology/hematology.

[14]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[15]  R. Winqvist,et al.  Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer , 2004, Journal of Medical Genetics.

[16]  K. Krause,et al.  BARD1 Expression During Spermatogenesis Is Associated with Apoptosis and Hormonally Regulated1 , 2004, Biology of reproduction.

[17]  C. Tropé,et al.  The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. , 1995, Gynecologic oncology.

[18]  T. Ludwig,et al.  Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability , 2003, Molecular and Cellular Biology.

[19]  T. Ohta,et al.  The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.

[20]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[21]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[22]  H. Kovar,et al.  Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. , 2002, Cancer research.

[23]  C. Jefford,et al.  Nuclear–cytoplasmic translocation of BARD1 is linked to its apoptotic activity , 2004, Oncogene.

[24]  S. Silverberg.  Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[25]  M. Morgan,et al.  Clinical characteristics of clear cell carcinoma of the ovary. , 1998, Gynecologic oncology.

[26]  J. Lafitte,et al.  Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.

[27]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[28]  E. Sensi,et al.  Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations , 2002, Genes, chromosomes & cancer.

[29]  W. El-Deiry,et al.  Clinical implication of p53 mutation in lung cancer , 2003, Molecular biotechnology.

[30]  J. Cain,et al.  Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. , 1996, Gynecologic oncology.

[31]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[32]  J. Ingle,et al.  Differential Gene Expression of TGFβ Inducible Early Gene (TIEG), Smad7, Smad2 and Bard1 in Normal and Malignant Breast Tissue , 2004, Breast Cancer Research and Treatment.

[33]  D. Livingston,et al.  Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Jefford,et al.  Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. , 2001, Molecular cell.

[35]  J. Zuber,et al.  Dissection of signal-regulated transcriptional modules by signaling pathway interference in oncogene-transformed cells. , 2003, Advances in enzyme regulation.

[36]  Ralph Scully,et al.  Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.

[37]  A. Gazdar,et al.  Abnormal expression of BRCA1 and BRCA1‐interactive DNA‐repair proteins in breast carcinomas , 2000, International journal of cancer.

[38]  M. Vidal,et al.  BRCA1/BARD1 Orthologs Required for DNA Repair in Caenorhabditis elegans , 2004, Current Biology.

[39]  Thomas Ludwig,et al.  The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. , 2002, Current opinion in genetics & development.

[40]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[41]  M. Santini,et al.  Analysis of cell cycle regulator proteins in non-small cell lung cancer , 2003, Journal of clinical pathology.

[42]  C. Lopes,et al.  Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Manley,et al.  Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. , 1999, Science.

[44]  A. N. Bartley,et al.  Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. , 2002, Archives of pathology & laboratory medicine.

[45]  J. Roth,et al.  p53 tumor suppressor gene therapy for cancer. , 1999, Oncology.

[46]  C. Mathew,et al.  Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer , 1998, Genes, chromosomes & cancer.

[47]  F. Zunino,et al.  Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. , 2003, Biochemical pharmacology.

[48]  T. Ouchi,et al.  Autoubiquitination of the BRCA1·BARD1 RING Ubiquitin Ligase* , 2002, The Journal of Biological Chemistry.

[49]  S. Tsutsui,et al.  Prognostic value of p53 protein expression in breast cancer; An immunohistochemical analysis of frozen sections in 514 Japanese women , 2001, Breast cancer.

[50]  A. Bowcock,et al.  Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein , 1998, Oncogene.

[51]  B. Henderson,et al.  BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. , 2004, Experimental cell research.

[52]  N. Hacker,et al.  Cyclin D 1 , p 53 , and p 21 Waf 1 / Cip 1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer , 2004 .

[53]  I. Irminger-Finger,et al.  In Vitro Repression of Brca1-associated RING Domain Gene, Bard1, Induces Phenotypic Changes in Mammary Epithelial Cells , 1998, The Journal of cell biology.

[54]  J. P. Geisler,et al.  Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. , 1998, European journal of gynaecological oncology.